Publications Authored by Oliver G Ottmann

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.

Authors:

Alessandro Rambaldi Josep-Maria Ribera Hagop M Kantarjian Hervé Dombret Oliver G Ottmann Anthony S Stein Catherine A Tuglus Xiaoyue Zhao Christopher Kim Giovanni Martinelli

Cancer 2020 Jan 18;126(2):304-310. Epub 2019 Oct 18.

Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola, Italy.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1002/cncr.32558	DOI Listing

January 2020

The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis.

Authors:

Afsar A Mian Ines Baumann Marcus Liebermann Florian Grebien Giulio Superti-Furga Martin Ruthardt Oliver G Ottmann Oliver Hantschel

Leukemia 2019 09 8;33(9):2319-2323. Epub 2019 Apr 8.

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1038/s41375-019-0468-y	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756289	PMC

September 2019

A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.

Authors:

Hartmut Döhner Carsten Müller-Tidow Michael Lübbert Walter Fiedler Alwin Krämer Jörg Westermann Gesine Bug Richard F Schlenk Utz Krug Rainer-Georg Goeldner James Hilbert Tillmann Taube Oliver G Ottmann

Br J Haematol 2019 May 19;185(3):583-587. Epub 2018 Nov 19.

Department of Medicine, Haematology/Oncology, Goethe University, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://doi.wiley.com/10.1111/bjh.15563	Publisher Site
http://dx.doi.org/10.1111/bjh.15563	DOI Listing

May 2019

Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.

Authors:

Oliver G Ottmann Carsten Müller-Tidow Alwin Krämer Richard F Schlenk Michael Lübbert Gesine Bug Utz Krug Tilmann Bochtler Florian Voss Tillmann Taube Dan Liu Pilar Garin-Chesa Hartmut Döhner

Br J Haematol 2019 Mar 8;184(6):1018-1021. Epub 2018 Jun 8.

Department of Internal Medicine III, University of Ulm, Ulm, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1111/bjh.15204	DOI Listing

March 2019

Genomic CDKN2A/2B deletions in adult Ph ALL are adverse despite allogeneic stem cell transplantation.

Blood 2018 03 18;131(13):1464-1475. Epub 2018 Jan 18.

Department of Hematology and Oncology and.

View Article

Download full-text PDF	Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2017-07	Publisher Site
http://dx.doi.org/10.1182/blood-2017-07-796862	DOI Listing

March 2018

CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.

Authors:

Mateusz Legut Garry Dolton Afsar Ali Mian Oliver G Ottmann Andrew K Sewell

Blood 2018 01 9;131(3):311-322. Epub 2017 Nov 9.

Division of Infection and Immunity, School of Medicine.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2017-05-787598	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774207	PMC

January 2018

Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.

Authors:

Fabian Lang Lydia Wunderle Heike Pfeifer Susanne Schnittger Gesine Bug Oliver G Ottmann

Am J Case Rep 2017 Oct 16;18:1099-1109. Epub 2017 Oct 16.

Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom.

View Article

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652250	PMC
http://dx.doi.org/10.12659/ajcr.904956	DOI Listing

October 2017

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.

Authors:

Nicola Gökbuget Gerhard Zugmaier Matthias Klinger Peter Kufer Matthias Stelljes Andreas Viardot Heinz A Horst Svenja Neumann Monika Brüggemann Oliver G Ottmann Thomas Burmeister Dorothea Wessiepe Max S Topp Ralf Bargou

Haematologica 2017 04 12;102(4):e132-e135. Epub 2017 Jan 12.

Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.3324/haematol.2016.153957	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395124	PMC

April 2017

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.

Authors:

Sarah Oelsner Miriam E Friede Congcong Zhang Juliane Wagner Susanne Badura Peter Bader Evelyn Ullrich Oliver G Ottmann Hans Klingemann Torsten Tonn Winfried S Wels

Cytotherapy 2017 02 22;19(2):235-249. Epub 2016 Nov 22.

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Germany. Electronic address:

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jcyt.2016.10.009	DOI Listing

February 2017

Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.

Authors:

Sarah Oelsner Juliane Wagner Miriam E Friede Verena Pfirrmann Sabrina Genßler Eva Rettinger Christian J Buchholz Heike Pfeifer Ralf Schubert Oliver G Ottmann Evelyn Ullrich Peter Bader Winfried S Wels

Int J Cancer 2016 10 11;139(8):1799-809. Epub 2016 Jun 11.

Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1002/ijc.30217	DOI Listing

October 2016

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL.

Blood 2016 08 27;128(6):774-82. Epub 2016 Apr 27.

Institute of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, United Kingdom.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2016-02-700153	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085255	PMC

August 2016

CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.

Authors:

Annette Romanski Christoph Uherek Gesine Bug Erhard Seifried Hans Klingemann Winfried S Wels Oliver G Ottmann Torsten Tonn

J Cell Mol Med 2016 07 23;20(7):1287-94. Epub 2016 Mar 23.

Institute for Transfusion Medicine and Immunohematology, J.W. Goethe University Frankfurt/Main, Red Cross Blood Donor Service Baden-Württemberg-Hessen, Dresden, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1111/jcmm.12810	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929308	PMC

July 2016

Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients.

Authors:

Tina Vetter Andreas Borowski Andreas Wohlmann Nilabh Ranjan Michael Kuepper Susanne Badura Oliver G Ottmann Karlheinz Friedrich

Leuk Res 2016 Jan 22;40:38-43. Epub 2015 Oct 22.

Jena University Hospital, Institute of Biochemistry II, Jena, Germany. Electronic address:

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.leukres.2015.10.003	DOI Listing

January 2016

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.

Authors:

Gabriela M Baerlocher Elisabeth Oppliger Leibundgut Oliver G Ottmann Gary Spitzer Olatoyosi Odenike Michael A McDevitt Alexander Röth Michael Daskalakis Bart Burington Monic Stuart David S Snyder

N Engl J Med 2015 Sep;373(10):920-8

From the Department of Hematology, University Hospital of Bern and University of Bern, Bern, Switzerland (G.M.B., E.O.L., M.D.); the Department of Hematology, School of Medicine, Cardiff University, Cardiff, United Kingdom (O.G.O.); Upstate Oncology Associates, Greenville, SC (G.S.); the Section of Hematology and Oncology, University of Chicago, Chicago (O.O.); the Divisions of Hematologic Malignancies and Hematology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore (M.A.M.); the Department of Hematology, University Hospital Essen, Essen, Germany (A.R.); and Geron, Menlo Park (B.B., M.S.), and the Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Gehr Family Center for Leukemia Research, Duarte (D.S.S.) - both in California.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1056/NEJMoa1503479	DOI Listing

September 2015

Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.

Authors:

Ruth Seggewiss-Bernhardt Ralf C Bargou Yeow Tee Goh A Keith Stewart Andrew Spencer Adrian Alegre Joan Bladé Oliver G Ottmann Cristina Fernandez-Ibarra Hong Lu Scott Pain Mikhail Akimov Swaminathan Padmanabhan Iyer

Cancer 2015 Jul 24;121(13):2185-92. Epub 2015 Mar 24.

Department of Hematology, Houston Methodist Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1002/cncr.29339	DOI Listing

July 2015

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

Authors:

Susanne Badura Tamara Tesanovic Heike Pfeifer Sylvia Wystub Bart A Nijmeijer Marcus Liebermann J H Frederik Falkenburg Martin Ruthardt Oliver G Ottmann

PLoS One 2013 14;8(11):e80070. Epub 2013 Nov 14.

Department of Medicine, Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0080070	PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828226	PMC

August 2014

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

Authors:

Hartmut Döhner Michael Lübbert Walter Fiedler Loic Fouillard Alf Haaland Joseph M Brandwein Stephane Lepretre Oumedaly Reman Pascal Turlure Oliver G Ottmann Carsten Müller-Tidow Alwin Krämer Emmanuel Raffoux Konstanze Döhner Richard F Schlenk Florian Voss Tillmann Taube Holger Fritsch Johan Maertens

Blood 2014 Aug 8;124(9):1426-33. Epub 2014 Jul 8.

University Hospital Gasthuisberg Leuven, Leuven, Belgium.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2014-03-560557	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148765	PMC

August 2014

Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.

Authors:

Gesine Bug Steffen Koschmieder Juergen Krauter Michael Heuser Felicitas Thol Stefanie Wiebe Wolf-Karsten Hofmann Stefan A Klein Gerd Wegener Gudrun Göhring Wolfgang Heit Dieter Hoelzer Arnold Ganser Oliver G Ottmann

Ann Hematol 2014 Feb 27;93(2):193-202. Epub 2013 Aug 27.

Department of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1007/s00277-013-1873-3	DOI Listing

February 2014

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.

Authors:

Elias Jabbour Oliver G Ottmann Michael Deininger Andreas Hochhaus

Haematologica 2014 Jan;99(1):7-18

View Article

Download full-text PDF	Source
http://dx.doi.org/10.3324/haematol.2013.087171	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007928	PMC

January 2014

Treatment of patients with advanced cancer with the natural killer cell line NK-92.

Authors:

Torsten Tonn Dirk Schwabe Hans G Klingemann Sven Becker Ruth Esser Ulrike Koehl Meinolf Suttorp Erhard Seifried Oliver G Ottmann Gesine Bug

Cytotherapy 2013 Dec 1;15(12):1563-70. Epub 2013 Oct 1.

Institute for Transfusion Medicine and Immunohematology, Goethe University Hospital, Frankfurt am Main, Germany; German Red Cross Blood Donation Service, Baden-Württemberg-Hessen, Germany. Electronic address:

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jcyt.2013.06.017	DOI Listing

December 2013

Endoplasmic reticulum protein GliPR1 regulates G protein signaling and the cell cycle and is overexpressed in AML.

Authors:

Gianni Capalbo Thea Mueller-Kuller Steffen Koschmieder Hans-Ulrich Klein Oliver G Ottmann Dieter Hoelzer Urban J Scheuring

Oncol Rep 2013 Nov 4;30(5):2254-62. Epub 2013 Sep 4.

Department of Hematology/Oncology and Infectious Diseases, J.W. Goethe University Hospital, D‑60590 Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.3892/or.2013.2716	DOI Listing

November 2013

A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.

Authors:

Carsten Müller-Tidow Gesine Bug Michael Lübbert Alwin Krämer Jürgen Krauter Peter Valent David Nachbaur Wolfgang E Berdel Oliver G Ottmann Holger Fritsch Gerd Munzert Pilar Garin-Chesa Frank Fleischer Tillmann Taube Hartmut Döhner

Br J Haematol 2013 Oct 16;163(2):214-22. Epub 2013 Aug 16.

Department of Medicine, Haematology and Oncology, University of Münster, Münster, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1111/bjh.12518	DOI Listing

October 2013

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.

Authors:

Carlos Graux Anne Sonet Johan Maertens Justus Duyster Jochen Greiner Yves Chalandon Giovanni Martinelli Dagmar Hess Dominik Heim Francis J Giles Kevin R Kelly Athos Gianella-Borradori Blandine Longerey Ekaterine Asatiani Narmyn Rejeb Oliver G Ottmann

Leuk Res 2013 Sep 5;37(9):1100-6. Epub 2013 Jun 5.

Mont-Godinne University Hospital (UCL), Yvoir, Belgium.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.leukres.2013.04.025	DOI Listing

September 2013

Characterization of ZC3H15 as a potential TRAF-2-interacting protein implicated in the NFκB pathway and overexpressed in AML.

Authors:

Gianni Capalbo Thea Mueller-Kuller Steffen Koschmieder Hans-Ulrich Klein Oliver G Ottmann Dieter Hoelzer Urban J Scheuring

Int J Oncol 2013 Jul 29;43(1):246-54. Epub 2013 Apr 29.

Department of Hematology/Oncology and Infectious Diseases, J.W. Goethe-University Hospital, 60595 Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.3892/ijo.2013.1924	DOI Listing

July 2013

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.

Authors:

Francis J Giles Ophelia Q P Yin William M Sallas Philipp D le Coutre Richard C Woodman Oliver G Ottmann Michele Baccarani Hagop M Kantarjian

Eur J Clin Pharmacol 2013 Apr 5;69(4):813-23. Epub 2012 Oct 5.

HRB Clinical Research Facility, Galway, and Trinity College, National University of Ireland, Dublin, Ireland.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1007/s00228-012-1385-4	DOI Listing

April 2013

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

Blood 2012 Dec 28;120(26):5185-7. Epub 2012 Sep 28.

Department of Internal Medicine II, University Würzburg, Würzburg, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2012-07-441030	DOI Listing

December 2012

HIV-1 infection suppresses expression of host cell cycle-associated gene PDS5A.

Authors:

Gianni Capalbo Thea Müller-Kuller Oliver G Ottmann Dieter Hoelzer Urban J Scheuring

Intervirology 2012 25;55(4):263-75. Epub 2011 Aug 25.

Department of Hematology/Oncology and Infectious Diseases, Johann Wolfgang Goethe University Hospital, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1159/000328323	DOI Listing

September 2012

Polo-like kinases in AML.

Authors:

Tobias Berg Gesine Bug Oliver G Ottmann Klaus Strebhardt

Expert Opin Investig Drugs 2012 Aug 6;21(8):1069-74. Epub 2012 Jun 6.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1517/13543784.2012.691163	DOI Listing

August 2012

p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

Authors:

Afsar A Mian Anna Metodieva Yousef Najajreh Oliver G Ottmann Jamal Mahajna Martin Ruthardt

Haematologica 2012 Feb 4;97(2):251-7. Epub 2011 Nov 4.

Department of Hematology, Goethe University, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.3324/haematol.2011.047191	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269486	PMC

February 2012

Knockdown of ERM family member moesin in host cells increases HIV type 1 replication.

Authors:

Gianni Capalbo Thea Mueller-Kuller Sandra Markovic Stefan A Klein Ursula Dietrich Dieter Hoelzer Oliver G Ottmann Urban J Scheuring

AIDS Res Hum Retroviruses 2011 Dec 19;27(12):1317-22. Epub 2011 May 19.

Department of Hematology/Oncology and Infectious Diseases, J. W. Goethe-University Hospital, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1089/AID.2010.0147	DOI Listing

December 2011

Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.

Authors:

Ruriko Tanaka Shinya Kimura Eishi Ashihara Mariko Yoshimura Naoto Takahashi Hisashi Wakita Kuniaki Itoh Kaichi Nishiwaki Kenshi Suzuki Rina Nagao Hisayuki Yao Yoshihiro Hayashi Sakiko Satake Hideyo Hirai Ken-Ichi Sawada Oliver G Ottmann Junia V Melo Taira Maekawa

Cancer Lett 2011 Dec 22;312(2):228-34. Epub 2011 Aug 22.

Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Japan.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.canlet.2011.08.009	DOI Listing

December 2011

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid.

Authors:

Andrea Kuendgen Gesine Bug Oliver G Ottmann Detlef Haase Julie Schanz Barbara Hildebrandt Kathrin Nachtkamp Judith Neukirchen Ariane Dienst Rainer Haas Ulrich Germing Norbert Gattermann

Clin Epigenetics 2011 Aug 8;2(2):389-99. Epub 2011 Apr 8.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1007/s13148-011-0031-9	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365387	PMC

August 2011

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

Authors:

Hagop M Kantarjian Francis J Giles Kapil N Bhalla Javier Pinilla-Ibarz Richard A Larson Norbert Gattermann Oliver G Ottmann Andreas Hochhaus Jerald P Radich Giuseppe Saglio Timothy P Hughes Giovanni Martinelli Dong-Wook Kim Yaping Shou Neil J Gallagher Rick Blakesley Michele Baccarani Jorge Cortes Philipp D le Coutre

Blood 2011 Jan 22;117(4):1141-5. Epub 2010 Nov 22.

The University of Texas M.D. Anderson Cancer Center, Leukemia Department, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2010-03-277152	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916554	PMC

January 2011

The DAC system and associations with acute leukemias and myelodysplastic syndromes.

Authors:

Gesine Bug Oliver G Ottmann

Invest New Drugs 2010 Dec 14;28 Suppl 1:S36-49. Epub 2010 Dec 14.

Medizinische Klinik II, Abteilung für Hämatologie und Onkologie der, Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1007/s10637-010-9595-z	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003828	PMC

December 2010

Inhibition of X4-tropic HIV type 1 replication by knockdown of the cellular protein LEREPO4.

Authors:

Gianni Capalbo Thea Müller-Kuller Ursula Dietrich Dieter Hoelzer Oliver G Ottmann Urban J Scheuring

AIDS Res Hum Retroviruses 2010 Oct 6;26(10):1155-61. Epub 2010 Oct 6.

Department of Hematology/Oncology and Infectious Diseases, J.W. Goethe-University Hospital, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1089/aid.2010.0041	DOI Listing

October 2010

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.

Authors:

Ruriko Tanaka Matthew S Squires Shinya Kimura Asumi Yokota Rina Nagao Takahiro Yamauchi Miki Takeuchi Hisayuki Yao Matthias Reule Tomoko Smyth John F Lyons Neil T Thompson Eishi Ashihara Oliver G Ottmann Taira Maekawa

Blood 2010 Sep 14;116(12):2089-95. Epub 2010 Jun 14.

Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2009-03-211466	DOI Listing

September 2010

Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndrome.

Authors:

Saskia Gueller Martina Komor Daniel Nowak Claudia D Baldus Sven de Vos Dieter Hoelzer Oliver G Ottmann Wolf-K Hofmann

Exp Hematol 2010 Sep 1;38(9):718-32, 732.e1-6. Epub 2010 Jun 1.

Department of Hematology and Oncology, University Hospital, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.exphem.2010.04.018	DOI Listing

September 2010

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors:

Oliver G Ottmann Heike Pfeifer

Hematology Am Soc Hematol Educ Program 2009 :371-81

Medizinische Klinik II, Department of Hematology and Oncology, Goethe University, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/asheducation-2009.1.371	DOI Listing

March 2010

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.

Authors:

Michael B Lilly Oliver G Ottmann Neil P Shah Richard A Larson Josy J Reiffers Gerhard Ehninger Martin C Müller Aude Charbonnier Eduardo Bullorsky Herve Dombret Mary Brigid Bradley-Garelik Chao Zhu Giovanni Martinelli

Am J Hematol 2010 Mar;85(3):164-70

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, USA.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1002/ajh.21615	DOI Listing

March 2010

Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression.

Authors:

Gianni Capalbo Thea Müller-Kuller Ursula Dietrich Dieter Hoelzer Oliver G Ottmann Urban J Scheuring

Retrovirology 2010 Mar 31;7:26. Epub 2010 Mar 31.

Department of Hematology/Oncology and Infectious Diseases, J. W. Goethe-University Hospital, Theodor Stern Kai 7, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1186/1742-4690-7-26	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859388	PMC

March 2010

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:

Oliver G Ottmann Barbara Wassmann

Hematology Am Soc Hematol Educ Program 2005 :118-22

Universitatsklinik Frankfurt, Medizinische Klinik III, Theodor-Stern-Kai 7, Frankfurt D-60590, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/asheducation-2005.1.118	DOI Listing

November 2009

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

Authors:

Michael Dickinson David Ritchie Daniel J DeAngelo Andrew Spencer Oliver G Ottmann Thomas Fischer Kapil N Bhalla Angela Liu Katie Parker Jeffrey W Scott Mark Bishton H Miles Prince

Br J Haematol 2009 Oct 5;147(1):97-101. Epub 2009 Aug 5.

Haematology Service, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1111/j.1365-2141.2009.07837.x	DOI Listing

October 2009

First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.

Authors:

Oliver G Ottmann Heike Pfeifer

Curr Opin Oncol 2009 Jun;21 Suppl 1:S43-6

Medizinische Klinik II, Department of Hematology and Oncology, Goethe University, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1097/01.cco.0000357476.43164.6b	DOI Listing

June 2009

Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors.

Authors:

Bart A Nijmeijer Karoly Szuhai Henriëtte M Goselink Marianke L J van Schie Marja van der Burg Danielle de Jong Erik W Marijt Oliver G Ottmann Roel Willemze J H Frederik Falkenburg

Exp Hematol 2009 Mar 9;37(3):376-85. Epub 2009 Jan 9.

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.exphem.2008.11.002	DOI Listing

March 2009

The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.

Authors:

Patricia Mambou Gwanmesia Annette Romanski Kerstin Schwarz Biserka Bacic Martin Ruthardt Oliver G Ottmann

BMC Cancer 2009 Feb 13;9:53. Epub 2009 Feb 13.

Med, Klinik II/Abt, Hämatologie, Johann Wolfgang Goethe-Universität, 60590 Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1186/1471-2407-9-53	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654659	PMC

February 2009

Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.

Authors:

Joerg Baeumler Karoly Szuhai J H Frederik Falkenburg Marianke L J van Schie Oliver G Ottmann Bart A Nijmeijer

Cancer Genet Cytogenet 2008 Aug;185(1):37-42

Department of Hematology, JW Goethe University, Frankfurt am Main, Germany.

View Article

Download full-text PDF	Source
http://linkinghub.elsevier.com/retrieve/pii/S016546080800278	Publisher Site
http://dx.doi.org/10.1016/j.cancergencyto.2008.05.001	DOI Listing

August 2008

Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.

Authors:

Paul La Rosée Susanne Holm-Eriksen Heiko Konig Nicolai Härtel Thomas Ernst Julia Debatin Martin C Mueller Philipp Erben Anja Binckebanck Lydia Wunderle Yaping Shou Margaret Dugan Ruediger Hehlmann Oliver G Ottmann Andreas Hochhaus

Haematologica 2008 May 26;93(5):765-9. Epub 2008 Mar 26.

III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3 68167 Mannheim, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.3324/haematol.12186	DOI Listing

May 2008

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.

Blood 2008 Feb 29;111(4):1834-9. Epub 2007 Nov 29.

Campus Virchow Klinikum, Charité Universitätsmedizin, Berlin, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2007-04-083196	DOI Listing

February 2008

Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis.

Authors:

Gesine Bug Konstantinos Anargyrou Torsten Tonn Heike Bialleck Erhard Seifried Dieter Hoelzer Oliver G Ottmann

Transfusion 2007 Oct;47(10):1843-50

Department of Internal Medicine II, University Hospital, Johann Wolfgang Goethe-University, Theodor Stern-Kai 7, D-60590 Frankfurt am Main, Germany.

View Article

Download full-text PDF	Source
http://doi.wiley.com/10.1111/j.1537-2995.2007.01406.x	Publisher Site
http://dx.doi.org/10.1111/j.1537-2995.2007.01406.x	DOI Listing

October 2007

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors:

Heike Pfeifer Barbara Wassmann Anna Pavlova Lydia Wunderle Johannes Oldenburg Anja Binckebanck Thoralf Lange Andreas Hochhaus Silvia Wystub Patrick Brück Dieter Hoelzer Oliver G Ottmann

Blood 2007 Jul 3;110(2):727-34. Epub 2007 Apr 3.

Center for Internal Medicine, Department of Hematology/Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2006-11-05	Publisher Site
http://dx.doi.org/10.1182/blood-2006-11-052373	DOI Listing

July 2007

An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.

Authors:

Martin C Müller Guiseppe Saglio Feng Lin Heike Pfeifer Richard D Press Raymond R Tubbs Peter Paschka Enrico Gottardi Steven G O'Brien Oliver G Ottmann Hubertus Stockinger Lothar Wieczorek Kirsten Merx Heiko König Uwe Schwindel Rüdiger Hehlmann Andreas Hochhaus

Haematologica 2007 Jul;92(7):970-3

III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.3324/haematol.11172	DOI Listing

July 2007

Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia.

Authors:

Oliver G Ottmann Gesine Bug Jürgen Krauter

Semin Hematol 2007 Jul;44(3):183-92

Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://linkinghub.elsevier.com/retrieve/pii/S003719630700070	Publisher Site
http://dx.doi.org/10.1053/j.seminhematol.2007.04.007	DOI Listing

July 2007

Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

Authors:

Oliver G Ottmann Barbara Wassmann Heike Pfeifer Aristoteles Giagounidis Matthias Stelljes Ulrich Dührsen Marc Schmalzing Lydia Wunderle Anja Binckebanck Dieter Hoelzer

Cancer 2007 May;109(10):2068-76

Department of Hematology, University Hospital of Frankfürt, Germany.

View Article

Download full-text PDF	Source
http://doi.wiley.com/10.1002/cncr.22631	Publisher Site
http://dx.doi.org/10.1002/cncr.22631	DOI Listing

May 2007

Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.

Authors:

Stefan Fruehauf Julian Topaly Eike C Buss Thomas Fischer Oliver G Ottmann Bertold Emmerich Martin C Müller Peter Schuld Leopold Balleisen Rüdiger Hehlmann Anthony D Ho Andreas Hochhaus

Cancer 2007 Apr;109(8):1543-9

Internal Medicine V, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1002/cncr.22535	DOI Listing

April 2007

Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.

Authors:

Gesine Bug Kerstin Schwarz Claudia Schoch Manuela Kampfmann Reinhard Henschler Dieter Hoelzer Oliver G Ottmann Martin Ruthardt

Haematologica 2007 Apr;92(4):542-5

Medizinische Klinik II, Abt. Hämatologie/Onkologie, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.3324/haematol.10758	DOI Listing

April 2007

Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.

Authors:

Christian Wichmann Linping Chen Markus Heinrich Daniela Baus Edith Pfitzner Martin Zörnig Oliver G Ottmann Manuel Grez

Cancer Res 2007 Mar;67(5):2280-9

Institute for Biomedical Research, Georg-Speyer-Haus, Paul-Ehrlich-Strasse 42-44, 60596 Frankfurt/M, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-3360	DOI Listing

March 2007

Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiation.

Authors:

Steffen Koschmieder Shuchi Agrawal Hanna S Radomska Claudia S Huettner Daniel G Tenen Oliver G Ottmann Wolfgang E Berdel Hubert L Serve Carsten Müller-Tidow

Int J Oncol 2007 Feb;30(2):349-55

Department of Internal Medicine-Hematology and Oncology, University Hospital of Münster, Germany.

View Article

Download full-text PDF	Source

February 2007

Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.

Authors:

Junya Kuroda Hamsa Puthalakath Mark S Cragg Priscilla N Kelly Philippe Bouillet David C S Huang Shinya Kimura Oliver G Ottmann Brian J Druker Andreas Villunger Andrew W Roberts Andreas Strasser

Proc Natl Acad Sci U S A 2006 Oct 22;103(40):14907-12. Epub 2006 Sep 22.

The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1073/pnas.0606176103	DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1595449	PMC

October 2006

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Blood 2006 Sep 25;108(5):1469-77. Epub 2006 Apr 25.

Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2005-11-4386	DOI Listing

September 2006

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Authors:

Hagop Kantarjian Francis Giles Lydia Wunderle Kapil Bhalla Susan O'Brien Barbara Wassmann Chiaki Tanaka Paul Manley Patricia Rae William Mietlowski Kathy Bochinski Andreas Hochhaus James D Griffin Dieter Hoelzer Maher Albitar Margaret Dugan Jorge Cortes Leila Alland Oliver G Ottmann

N Engl J Med 2006 Jun;354(24):2542-51

Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1402, USA.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1056/NEJMoa055104	DOI Listing

June 2006

FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment.

Authors:

Dali Cai Ying Wang Oliver G Ottmann Peter J Barth Andreas Neubauer Andreas Burchert

Blood 2006 Mar 22;107(5):2094-7. Epub 2005 Nov 22.

Universitätsklinikum Marburg und Giessen, Standort Marburg, Klinik für Hämatologie, Onkologie, und Immunologie, Marburg, Germany.

View Article

Download full-text PDF	Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2005-08-33	Publisher Site
http://dx.doi.org/10.1182/blood-2005-08-3317	DOI Listing

March 2006

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.

Authors:

Gesine Bug Markus Ritter Barbara Wassmann Claudia Schoch Thorsten Heinzel Kerstin Schwarz Annette Romanski Oliver H Kramer Manuela Kampfmann Dieter Hoelzer Andreas Neubauer Martin Ruthardt Oliver G Ottmann

Cancer 2005 Dec;104(12):2717-25

Department of Internal Medicine II, University Hospital, JW Goethe-University Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1002/cncr.21589	DOI Listing

December 2005

Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiation.

Authors:

Martina Komor Saskia Güller Claudia D Baldus Sven de Vos Dieter Hoelzer Oliver G Ottmann Wolf-K Hofmann

Stem Cells 2005 Sep 13;23(8):1154-69. Epub 2005 Jun 13.

Department of Hematology, Oncology and Transfusion Medicine, University Hospital Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1634/stemcells.2004-0171	DOI Listing

September 2005

Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth.

Authors:

Hidekazu Segawa Shinya Kimura Junya Kuroda Kiyoshi Sato Asumi Yokota Eri Kawata Yuri Kamitsuji Eishi Ashihara Takeshi Yuasa Yoshihide Fujiyama Oliver G Ottmann Taira Maekawa

Br J Haematol 2005 Aug;130(4):558-60

Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1111/j.1365-2141.2005.05648.x	DOI Listing

August 2005

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors:

Barbara Wassmann Heike Pfeifer Michael Stadler Martin Bornhaüser Gesine Bug Urban J Scheuring Patrick Brück Matthias Stelljes Rainer Schwerdtfeger Nadezda Basara Jolanta Perz Donald Bunjes Georg Ledderose Rolf Mahlberg Anja Binckebanck Harald Gschaidmeier Dieter Hoelzer Oliver G Ottmann

Blood 2005 Jul 7;106(2):458-63. Epub 2005 Apr 7.

Departments of Hematology/Oncology of University Hospitals Frankfurt, Hannover, Dresden, Münster, Ulm, Heidelberg, Munich, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2004-05-1746	DOI Listing

July 2005

Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.

Authors:

Annette Romanski Gesine Bug Sven Becker Manuela Kampfmann Erhard Seifried Dieter Hoelzer Oliver G Ottmann Torsten Tonn

Exp Hematol 2005 Mar;33(3):344-52

Center for Internal Medicine, Department of Hematology/Oncology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.exphem.2004.11.006	DOI Listing

March 2005

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Authors:

Walter Fiedler Hubert Serve Hartmut Döhner Michael Schwittay Oliver G Ottmann Anne-Marie O'Farrell Carlo L Bello Randy Allred William C Manning Julie M Cherrington Sharianne G Louie Weiru Hong Nicoletta M Brega Giorgio Massimini Paul Scigalla Wolfgang E Berdel Dieter K Hossfeld

Blood 2005 Feb 30;105(3):986-93. Epub 2004 Sep 30.

Department of Oncology/Hematology, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2004-05-1846	DOI Listing

February 2005

Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms.

Authors:

Patrick Brück Barbara Wassmann Elizabeth Ramos Lopez Dieter Hoelzer Oliver G Ottmann

Leuk Res 2004 Nov;28(11):1153-7

Department of Hematology and Oncology, Medizinische Klinik III, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt a.M., Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.leukres.2004.03.007	DOI Listing

November 2004

Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.

Authors:

Annette Romanski Biserka Bacic Gesine Bug Heike Pfeifer Hilal Gul Stacy Remiszewski Dieter Hoelzer Peter Atadja Martin Ruthardt Oliver G Ottmann

Haematologica 2004 Apr;89(4):419-26

Med. Klinik III/Abtl. Hämatologie, Johann Wolfgang Goethe-Universität, 60590 Frankfurt, Germany.

View Article

Download full-text PDF	Source

April 2004

Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia.

Authors:

Wolf-K Hofmann Martina Komor Dieter Hoelzer Oliver G Ottmann

Leuk Lymphoma 2004 Apr;45(4):655-60

Department of Hematology and Oncology, University Hospital, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1080/10428190310001625755	DOI Listing

April 2004

Regulation of human IL-18 gene expression: interaction of PU.1 with GC-box binding protein is involved in human IL-18 expression in myeloid cells.

Authors:

Noriko Koyama Dieter Hoelzer Oliver G Ottmann

Eur J Immunol 2004 Mar;34(3):817-826

Department of Hematology, Johann Wolfgang Goethe University, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1002/eji.200324420	DOI Listing

March 2004

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.

Authors:

Barbara Wassmann Heike Pfeifer Urban J Scheuring Anja Binckebanck Nicola Gökbuget Johannes Atta Patrick Brück Harald Rieder Claudia Schoch Lothar Leimer Rainer Schwerdtfeger Gerhard Ehninger Thomas Lipp Jolanta Perz Matthias Stelljes Harald Gschaidmeier Dieter Hoelzer Oliver G Ottmann

Blood 2004 Feb 23;103(4):1495-8. Epub 2003 Oct 23.

Department of Hematology/Oncology, University Hospital Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://www.bloodjournal.org/content/103/4/1495.full.pdf	Web Search
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2003-01-01	Publisher Site
http://dx.doi.org/10.1182/blood-2003-01-0154	DOI Listing

February 2004

p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.

Authors:

Junya Kuroda Shinya Kimura Hidekazu Segawa Kiyoshi Sato Seiji Matsumoto Masaki Nogawa Takeshi Yuasa Yutaka Kobayashi Toshikazu Yoshikawa Oliver G Ottmann Taira Maekawa

Cancer Sci 2004 Feb;95(2):186-92

Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1111/j.1349-7006.2004.tb03202.x	DOI Listing

February 2004

Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.

Authors:

Shinya Kimura Junya Kuroda Hidekazu Segawa Kiyoshi Sato Masaki Nogawa Takeshi Yuasa Oliver G Ottmann Taira Maekawa

Int J Hematol 2004 Jan;79(1):37-43

Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1007/bf02983531	DOI Listing

January 2004

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

Authors:

Walter Fiedler Rolf Mesters Heike Tinnefeld Sonja Loges Peter Staib Ulrich Duhrsen Michael Flasshove Oliver G Ottmann Wolfram Jung Franco Cavalli Rolf Kuse Joerg Thomalla Hubert Serve Anne M O'Farrell Mark Jacobs Nicoletta M Brega Paul Scigalla Dieter K Hossfeld Wolfgang E Berdel

Blood 2003 Oct 3;102(8):2763-7. Epub 2003 Jul 3.

Department of Oncology/Hematology, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2002-10-2998	DOI Listing

October 2003

Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.

Authors:

Elena Puccetti Tim Beissert Saskia Güller Jun E Li Dieter Hoelzer Oliver G Ottmann Martin Ruthardt

Oncogene 2003 Oct;22(44):6900-8

Med. Klinik III/Abtl. Hämatologie, Johann Wolfgang Goethe-Universität, D-60590 Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1038/sj.onc.1206747	DOI Listing

October 2003

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.

Authors:

Heike Pfeifer Barbara Wassmann Wolf-Karsten Hofmann Martina Komor Urban Scheuring Patrick Brück Anja Binckebanck Eberhard Schleyer Nicola Gökbuget Thomas Wolff Michael Lübbert Lothar Leimer Harald Gschaidmeier Dieter Hoelzer Oliver G Ottmann

Clin Cancer Res 2003 Oct;9(13):4674-81

Department of Hematology, Johann Wolfgang Goethe-Universität, 60590 Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://www.gacguidelines.ca/site/GAC_Guidelines/assets/pdf/3	Web Search

October 2003

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.

Authors:

Junya Kuroda Shinya Kimura Hidekazu Segawa Yutaka Kobayashi Toshikazu Yoshikawa Yoshimasa Urasaki Takanori Ueda Fumio Enjo Harukuni Tokuda Oliver G Ottmann Taira Maekawa

Blood 2003 Sep 22;102(6):2229-35. Epub 2003 May 22.

Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2003-01-0305	DOI Listing

September 2003

Methodologic and biological variability of quantitative real-time polymerase chain reaction analysis of Bcr-Abl expression in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:

Urban J Scheuring Heike Pfeifer Barbara Wassmann Patrick Brück Dieter Hoelzer Oliver G Ottmann

Haematologica 2003 Sep;88(9):1074-6

View Article

Download full-text PDF	Source

September 2003

The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.

Authors:

Oliver G Ottmann Dieter Hoelzer

Hematol J 2002 ;3(1):2-6

Medizinische Klinik III, Department of Hematology and Oncology, Johann Wolfgang Goethe-Universität, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1038/sj.thj.6200151	DOI Listing

July 2003

Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.

Authors:

Wolf-Karsten Hofmann Martina Komor Barbara Wassmann Letetia C Jones Harald Gschaidmeier Dieter Hoelzer H Phillip Koeffler Oliver G Ottmann

Blood 2003 Jul 27;102(2):659-61. Epub 2003 Mar 27.

Department of Hematology, University Hospital, Theodor-Stern-Kai 7, 60596, Frankfurt/Main, Germany.

View Article

Download full-text PDF	Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2002-06-17	Publisher Site
http://dx.doi.org/10.1182/blood-2002-06-1756	DOI Listing

July 2003

Comparison of TaqMan real-time PCR and p24 Elisa for quantification of in vitro HIV-1 replication.

Authors:

Stefan A Klein Susanne Karsten Brigitte Rüster Christian Klebba Martine Pape Oliver G Ottmann Dieter Hoelzer Willi K Roth

J Virol Methods 2003 Feb;107(2):169-75

Medizinische Klinik III der Johann Wolfgang Goethe Universität, Theodor-Stern Kai 7, D-60590, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1016/s0166-0934(02)00230-6	DOI Listing

February 2003

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

Authors:

Urban J Scheuring Heike Pfeifer Barbara Wassmann Patrick Bruck Johannes Atta Eduard K Petershofen Brigitte Gehrke Harald Gschaidmeier Dieter Hoelzer Oliver G Ottmann

Blood 2003 Jan 22;101(1):85-90. Epub 2002 Aug 22.

Medizinische Klinik III, Abteilung für Hämatologie und Onkologie of the Johann Wolfgang Goethe-Universität, Frankfurt, Germany.

View Article

Download full-text PDF	Source
http://dx.doi.org/10.1182/blood-2002-02-0360	DOI Listing

January 2003

Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts.

Authors:

Oliver G Ottmann Barbara Wassmann

Best Pract Res Clin Haematol 2002 Dec;15(4):757-69

Medizinische Klinik III, Abteilung für Hämatologie und Onkologie, Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, D-60590, Frankfurt, Germany.

View Article